High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma.
BACKGROUND
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays an important role in the treatment of aggressive non-Hodgkin's lymphoma (NHL). We report on a retrospective analysis of all patients with diffuse large B-cell lymphoma who were consecutively treated with HDT followed by ASCT at the University Hospital of Bonn, Germany, between 1996 and 2004.


METHODS
A total of 25 patients were transplanted for biopsy-proven diffuse large B-cell lymphoma (DLBCL). Eight patients received up-front HDT as first-line therapy, four patients received HDT due to incomplete response to conventional induction chemotherapy, and six patients were treated for primary refractory disease. Seven patients had recurrent lymphoma.


RESULTS
A complete remission (CR) was achieved in 14 of 25 patients (56%). Estimated 3-year survival for patients treated with upfront HDT, chemosensitive patients with incomplete response to first line therapy, and patients with chemosensitive relapsed disease was 87.5%, 50.0% and 60.0%, respectively. In contrast, no patient with primary refractory disease or relapsed disease lacking chemosensitivity lived longer than 8 months. Chemosensitivity was the only significant prognostic factor for overall survival (OS) in multivariate analysis.


CONCLUSIONS
Our results confirm that HDT and ASCT is a highly effective therapy in patients with DLBCL leading to long-term survival in a substantial proportion of patients. Patients treated upfront for high-risk disease, incomplete response to conventional first-line therapy, or for chemosensitive relapse have a good prognosis. In contrast, patients with primary chemorefractory disease and patients with relapsed disease lacking chemosensitivity do not benefit from HDT with ASCT.
Mey
Ulrich J M
UJ
Department of Internal Medicine I, University of Bonn, Bonn, Germany. Ulrich.Mey@ukb.uni-bonn.de
Jha
Vandana
V
Strehl
John W
JW
Gorschlueter
Marcus
M
Rabe
Christian
C
Hoebert
Eckfried
E
Popp
Henning
H
Schmidt-Wolf
Ingo G H
IG
J Clin Oncol. 1996 Feb;14(2):534-42
8636768
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20
12042984
N Engl J Med. 1995 Apr 20;332(16):1045-51
7898521
J Clin Oncol. 2001 Jan 15;19(2):406-13
11208832
Ann Oncol. 2005 Aug;16(8):1359-65
15939712
J Clin Oncol. 2002 May 15;20(10):2472-9
12011124
J Clin Oncol. 1993 Oct;11(10):1841-3
8105033
J Clin Oncol. 1995 Mar;13(3):588-95
7884420
Leuk Lymphoma. 2006 Dec;47(12):2558-66
17169800
Br J Haematol. 2005 Aug;130(3):363-72
16042685
Ann Oncol. 1997 Nov;8(11):1125-32
9426332
J Clin Oncol. 1998 Aug;16(8):2796-802
9704732
J Clin Oncol. 2002 Nov 15;20(22):4413-9
12431962
J Clin Oncol. 1996 Feb;14(2):586-92
8636775
N Engl J Med. 2004 Mar 25;350(13):1287-95
15044639
J Clin Oncol. 1997 Mar;15(3):1131-7
9060555
Ann Oncol. 1996 Dec;7(10):1043-9
9037363
Blood. 1998 Nov 15;92(10):3562-8
9808548
J Clin Oncol. 1998 Jan;16(1):48-55
9440722
Br J Haematol. 1996 Mar;92(4):880-9
8616081
J Natl Cancer Inst. 2001 Jan 3;93(1):22-30
11136838
J Clin Oncol. 1999 Apr;17(4):1244
10561185
Korean J Intern Med. 2004 Jun;19(2):114-20
15366643
N Engl J Med. 1997 May 1;336(18):1290-7
9113932
Hematol Oncol. 1994 Mar-Apr;12(2):75-85
8070756
N Engl J Med. 1995 Dec 7;333(23):1540-5
7477169
Haematologica. 2000 Sep;85(9):943-51
10980633
J Clin Oncol. 2000 Jan;18(2):332-9
10637247
J Clin Oncol. 1999 Jan;17(1):423-9
10458261
J Clin Oncol. 1998 Oct;16(10):3264-9
9779700
Ann Hematol. 2005 Aug;84(8):517-25
15759115
J Clin Oncol. 2000 Aug;18(16):3025-30
10944137
Blood. 2003 Sep 15;102(6):1989-96
12676776
J Clin Oncol. 1993 Dec;11(12):2351-61
8246024
J Clin Oncol. 1993 Oct;11(10):1846-51
8105034
Haematologica. 2003 Nov;88(11):1304-15
14607760
Blood. 2004 May 15;103(10):3684-8
14739217
J Clin Oncol. 2003 Apr 1;21(7):1255-62
12663712
Ann Oncol. 2004 Oct;15(10):1504-9
15367411
N Engl J Med. 1993 Sep 30;329(14):987-94
8141877
Ann Oncol. 1999 Apr;10(4):427-32
10370785
Cancer Invest. 2006 Oct;24(6):593-600
16982464